-$0.48 Earnings Per Share Expected for Inogen, Inc. (NASDAQ:INGN) This Quarter

Equities research analysts predict that Inogen, Inc. (NASDAQ:INGNGet Rating) will post earnings per share of ($0.48) for the current quarter, Zacks reports. Four analysts have provided estimates for Inogen’s earnings, with estimates ranging from ($0.57) to ($0.35). Inogen reported earnings per share of ($0.03) in the same quarter last year, which suggests a negative year over year growth rate of 1,500%. The business is scheduled to announce its next quarterly earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Inogen will report full year earnings of ($1.07) per share for the current fiscal year, with EPS estimates ranging from ($1.18) to ($0.90). For the next year, analysts anticipate that the firm will report earnings of ($0.26) per share, with EPS estimates ranging from ($0.50) to ($0.01). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that cover Inogen.

Inogen (NASDAQ:INGNGet Rating) last released its earnings results on Thursday, February 24th. The medical technology company reported ($1.01) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.74) by ($0.27). The business had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.60 million. Inogen had a negative return on equity of 1.70% and a negative net margin of 1.77%. The company’s revenue for the quarter was up 3.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.23) earnings per share.

INGN has been the subject of several recent analyst reports. TheStreet lowered Inogen from a “c-” rating to a “d” rating in a report on Friday, March 11th. StockNews.com started coverage on Inogen in a research report on Thursday, March 31st. They issued a “hold” rating for the company. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $49.80.

Inogen stock traded up $0.07 during midday trading on Monday, reaching $26.97. The stock had a trading volume of 190,370 shares, compared to its average volume of 190,327. The firm has a market cap of $613.16 million, a price-to-earnings ratio of -93.00 and a beta of 0.91. Inogen has a 12 month low of $26.19 and a 12 month high of $82.35. The business has a 50-day moving average of $31.39.

In other Inogen news, Director Ray Benjamin M. Anderson sold 4,516 shares of the stock in a transaction dated Thursday, March 3rd. The stock was sold at an average price of $34.68, for a total value of $156,614.88. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.29% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. grew its position in shares of Inogen by 86.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 11,885 shares of the medical technology company’s stock worth $404,000 after purchasing an additional 5,494 shares in the last quarter. Blueshift Asset Management LLC grew its holdings in Inogen by 254.1% during the 3rd quarter. Blueshift Asset Management LLC now owns 13,213 shares of the medical technology company’s stock valued at $569,000 after buying an additional 9,482 shares in the last quarter. Cubist Systematic Strategies LLC boosted its holdings in shares of Inogen by 139.3% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 44,793 shares of the medical technology company’s stock worth $1,930,000 after purchasing an additional 26,078 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Inogen by 1,764.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 32,256 shares of the medical technology company’s stock worth $1,389,000 after purchasing an additional 30,526 shares during the period. Finally, Barclays PLC boosted its holdings in shares of Inogen by 17.1% in the 3rd quarter. Barclays PLC now owns 19,009 shares of the medical technology company’s stock worth $819,000 after purchasing an additional 2,771 shares during the period. Hedge funds and other institutional investors own 93.22% of the company’s stock.

Inogen Company Profile (Get Rating)

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Read More

Get a free copy of the Zacks research report on Inogen (INGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.